The firm attributed growth to a diversified geographic footprint and comprehensive offerings based on three key in vitro diagnostics technologies.
The 20-gene assay, which BioMérieux will develop on the BioFire FilmArray platform, distinguishes active TB from latent TB, viral, and bacterial infections.
Sales were driven by a strong flu season and growth in Asia-Pacific business.
Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Sales of BioFire FilmArray products accounted for more than half of the growth in the quarter.
BioMérieux sees Qvella's system as complementary to its BioFire FilmArray and will consider adopting Qvella's sample treatment technology.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
New investor BioMérieux will explore collaborative opportunities using Qvella's sample treatment technology in complementary markets.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.